RECURSION PHARMACEUTICALS, INC.(RXRX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,728 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
RXRX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for RECURSION PHARMACEUTICALS, INC. (RXRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RXRX at 23.3/100 on a 32-signal composite quality model, placing it at rank #2,728 of 2,962 stocks — the bottom half of the AI-ranked universe. RXRX scores in the top quartile across institutional flow (88.8). Areas of concern include free cash flow (2.3) and profitability (2.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), RECURSION PHARMACEUTICALS, INC. reports quarterly revenue of $7.7M, net income of $-131.0M, free cash flow of $-106.0M. Top institutional holders of RXRX by reported 13-F value include BlackRock, ARK Investment Management, STATE STREET, based on the most recent SEC filings. RXRX trades on the Nasdaq exchange and files with the SEC under CIK 1601830. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RXRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RECURSION PHARMACEUTICALS, INC. directly from SEC EDGAR. RECURSION PHARMACEUTICALS, INC.'s 13F Pro composite quality score has ranged between 10 and 32 since 2022, currently 23.3 — a declining long-term trajectory across 64 quarterly and live scoring snapshots.
Revenue
Q2 2026
$7.7M
Net Income
Q2 2026
$-131.0M
Free Cash Flow
Q2 2026
$-106.0M
ROIC
Q2 2026
-58.1%
D/E Ratio
Q2 2026
0.02
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+26.9% YoYNet Income
-39.1% YoYOperating Income
-35.3% YoYEPS (Diluted)
+14.8% YoYTotal Assets
+1.8% YoYTotal Debt
-32.0% YoYOp. Cash Flow
-3.5% YoYFree Cash Flow
-1.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $74.7M +26.9% | $58.8M +32.0% | $44.6M +11.9% | $39.8M +291.5% | $10.2M +156.9% | $4.0M |
| Net Income | $-644.8M -39.1% | $-463.7M -41.3% | $-328.1M -37.0% | $-239.5M -28.4% | $-186.5M -114.3% | $-87.0M |
| Operating Income | $-648.1M -35.3% | $-479.0M -36.8% | $-350.1M -42.5% | $-245.7M -34.4% | $-182.8M -116.0% | $-84.6M |
| EPS (Diluted) | $-1.44 +14.8% | $-1.69 -7.0% | $-1.58 -16.2% | $-1.36 +8.7% | $-1.49 +44.0% | $-2.66 |
| Total Assets | $1.47B +1.8% | $1.45B +121.6% | $653.7M -6.8% | $701.3M +14.9% | $610.3M +104.4% | $298.6M |
| Total Debt | $18.7M -32.0% | $27.4M +2303.4% | $1.1M | — | $723.0K | — |
| Operating Cash Flow | $-371.8M -3.5% | $-359.2M -24.8% | $-287.8M -244.5% | $-83.5M +47.3% | $-158.6M -249.4% | $-45.4M |
| Free Cash Flow | $-378.3M -1.5% | $-372.9M -24.4% | $-299.7M -148.6% | $-120.6M +39.2% | $-198.4M -287.3% | $-51.2M |
Get alerted when RXRX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for RECURSION PHARMACEUTICALS, INC. including:
Top Institutional Holders of RXRX
BlackRock, Inc.
$184.6M50,304,691 shARK Investment Management LLC
$151.7M41,337,632 shSTATE STREET CORP
$127.4M34,706,130 shVANGUARD PORTFOLIO MANAGEMENT LLC
$114.3M31,131,599 shBAILLIE GIFFORD & CO
$86.2M23,487,907 shVANGUARD CAPITAL MANAGEMENT LLC
$83.6M22,765,940 shGEODE CAPITAL MANAGEMENT, LLC
$50.7M13,819,135 shSOFTBANK GROUP CORP.
$50.0M13,636,515 shMIC Capital Management UK LLP
$35.4M9,644,033 shUBS Group AG
$32.8M8,947,102 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $184.6M | 50,304,691 |
| ARK Investment Management LLC | $151.7M | 41,337,632 |
| STATE STREET CORP | $127.4M | 34,706,130 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $114.3M | 31,131,599 |
| BAILLIE GIFFORD & CO | $86.2M | 23,487,907 |
| VANGUARD CAPITAL MANAGEMENT LLC | $83.6M | 22,765,940 |
| GEODE CAPITAL MANAGEMENT, LLC | $50.7M | 13,819,135 |
| SOFTBANK GROUP CORP. | $50.0M | 13,636,515 |
| MIC Capital Management UK LLP | $35.4M | 9,644,033 |
| UBS Group AG | $32.8M | 8,947,102 |
Companies Similar to RXRX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Absci Corp
Ginkgo Bioworks Holdings, Inc.
CRISPR Therapeutics AG
BioAge Labs, Inc.
Evommune, Inc.
Relay Therapeutics, Inc.
Entrada Therapeutics, Inc.
Intellia Therapeutics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put RXRX on your watchlist
Track score changes the day RECURSION PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is RXRX a good stock to buy?
13F Pro's AI-powered analysis of RECURSION PHARMACEUTICALS, INC. (RXRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RXRX are available on the RXRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RXRX is classified as a small company.
Which hedge funds own RXRX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RXRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of RECURSION PHARMACEUTICALS, INC.'s investment landscape.